Spencer Phillip Pajk

This inventor holds 10 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Array Biopharma Inc., Mirati Therapeutics, Inc., Pfizer Corporation. Active years: 2020-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Spencer Phillip Pajk. Retrieved from https://idiyas.com/inventor/spencer-phillip-pajk

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 5)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 6)

Average Co-Inventor Count = 14.2

ph-index = 3

Forward Citations = 21(Granted Patents)

Company Filing History:

Mirati Therapeutics, Inc.

where one patent can have more than one assignee

Years Active: 2020-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12747253 - KRas G12D inhibitors (2026-09-29),

2. 12686692 - KRas G12D inhibitors (2026-07-21),

3. 12630566 - KRas G12D inhibitors (2026-05-19),

4. 12447153 - HER2 mutation inhibitors (2025-10-21),

5. 11964989 - KRas G12D inhibitors (2024-04-23),

6. 11834453 - Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors (2023-12-05),

7. 11634409 - Compounds for the treatment of BRAF-associated diseases and disorders (2023-04-25),

8. 11453683 - KRas G12D inhibitors (2022-09-27),

9. 11414404 - Compounds for the treatment of BRAF-associated diseases and disorders (2022-08-16),

10. 10647715 - KRas G12C inhibitors (2020-05-12),

Title: Spencer Pajk - Innovator in Cancer Treatment from Boulder, CO

Introduction:

Spencer Pajk, a talented inventor based in Boulder, CO, is making waves in the field of cancer treatment with his groundbreaking patent on KRas G12D inhibitors.

Latest Patents:

With a notable patent on KRas G12D inhibitors, Spencer Pajk has introduced compounds that showcase the potential to inhibit the activity of KRas G12D, offering new avenues for treating cancer. The compounds, represented by Formula (I) or a pharmaceutically acceptable salt thereof, hold promise in pharmaceutical compositions and methods aimed at combating cancer.

Career Highlights:

During his impressive career, Spencer Pajk has made pivotal contributions to the biopharmaceutical industry. He has lent his expertise to renowned companies such as Mirati Therapeutics, Inc. and Array Biopharma Inc., where he has played a crucial role in advancing innovative solutions for cancer therapies.

Collaborations:

Spencer Pajk has had the privilege of collaborating with standout individuals in the field, including Xiaolun Wang and Aaron Craig Burns. Together, they have worked towards revolutionizing the landscape of cancer treatment, pushing boundaries and exploring novel approaches to address this critical medical need.

Conclusion:

In conclusion, Spencer Pajk stands as a beacon of innovation in cancer research, with his patent on KRas G12D inhibitors paving the way for novel treatment modalities. His dedication, expertise, and collaborative spirit position him as a key figure in the ongoing quest to combat cancer effectively.

Profile summary based on public USPTO records.